- Report
- June 2026
- 200 Pages
Global
From €2817EUR$2,990USD£2,345GBP
- Report
- September 2026
- 189 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- November 2026
- 282 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- February 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- February 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- February 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- July 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- August 2025
- 200 Pages
United States
From €2346EUR$2,490USD£1,953GBP
- Report
- September 2024
- 82 Pages
Japan
From €3297EUR$3,500USD£2,745GBP
- Report
- December 2024
- 30 Pages
Global
From €2591EUR$2,750USD£2,157GBP
- Report
- September 2024
- 343 Pages
Global
From €7490EUR$7,950USD£6,236GBP
- Report
- September 2024
- 128 Pages
Global
From €14127EUR$14,995USD£11,762GBP
- Report
- April 2025
- 150 Pages
Global
From €4569EUR$4,850USD£3,804GBP
- Report
- July 2025
- 350 Pages
Global
From €4663EUR$4,949USD£3,882GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$3,980USD£3,016GBP
- Report
- July 2018
- 33 Pages
Global
From €9421EUR$10,000USD£7,844GBP
- Report
- February 2024
- 82 Pages
Global
From €3500EUR$3,980USD£3,016GBP

The Long Acting Muscarinic Antagonist (LAMA) market is a subset of the larger respiratory drug market. LAMAs are used to treat chronic obstructive pulmonary disease (COPD) and asthma. These drugs work by blocking the action of acetylcholine, a neurotransmitter that causes airway constriction. This helps to reduce symptoms such as coughing, wheezing, and shortness of breath. LAMAs are typically administered via inhalation, and are available in both short-acting and long-acting formulations. Long-acting formulations provide sustained relief from symptoms over a longer period of time.
Some of the major companies in the LAMA market include GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, and Merck. These companies produce a variety of LAMA drugs, including tiotropium, aclidinium, umeclidinium, and glycopyrronium. Show Less Read more